On Friday, Bicara Therapeutics Inc (NASDAQ: BCAX) was -10.65% drop from the session before settling in for the closing price of $11.83. A 52-week range for BCAX has been $11.10 – $28.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 57.59%. With a float of $30.95 million, this company’s outstanding shares have now reached $54.44 million.
Let’s look at the performance matrix of the company that is accounted for 55 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Bicara Therapeutics Inc (BCAX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bicara Therapeutics Inc stocks. The insider ownership of Bicara Therapeutics Inc is 43.23%, while institutional ownership is 55.47%. The most recent insider transaction that took place on Mar 14 ’25, was worth 1,021,211. In this transaction Chief Legal Officer of this company sold 79,146 shares at a rate of $12.90, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 14 ’25, when Company’s Officer proposed sale 79,146 for $13.35, making the entire transaction worth $1,056,599.
Bicara Therapeutics Inc (BCAX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.59% per share during the next fiscal year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
You can see what Bicara Therapeutics Inc (BCAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 27.93.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
Bicara Therapeutics Inc (NASDAQ: BCAX) saw its 5-day average volume 0.55 million, a positive change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 20.06%. Additionally, its Average True Range was 1.34.
During the past 100 days, Bicara Therapeutics Inc’s (BCAX) raw stochastic average was set at 0.35%, which indicates a significant decrease from 1.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.66% in the past 14 days, which was higher than the 79.60% volatility it showed in the past 100 days.
Nevertheless, the first resistance level for the watch stands at $11.70 in the near term. At $12.83, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.42. If the price goes on to break the first support level at $9.98, it is likely to go to the next support level at $9.39. The third support level lies at $8.26 if the price breaches the second support level.
Bicara Therapeutics Inc (NASDAQ: BCAX) Key Stats
There are 54,523K outstanding shares of the company, which has a market capitalization of 576.31 million. As of now, sales total 0 K while income totals -67,995 K. Its latest quarter income was 0 K while its last quarter net income were -20,957 K.
